Skip to main content

Table 2 Participant Clinical Characteristics 1

From: Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity

Participant Characteristics Total
N = 25*
Phase 1
N = 10
Phase II
N = 15
Doctor(s) seen for lupus1
 Primary care or general doctor 16 (64.0%) 7 (70.0%) 9 (60.0%)
 Lupus specialist or rheumatologist 25 (100%) 10 (100%) 15 (100%)
 Skin doctor or dermatologist 10 (40.0%) 4 (40.0%) 6 (40.0%)
 Kidney doctor or nephrologist 13 (52.0%) 6 (60.0%) 7 (46.7%)
Treatments or medications taken for lupus2
 Hydroxychloroquine (Plaquenil), Quinacrine (Atabrine), or Chloroquine 24 (96.0%) 10 (100%) 14 (93.3%)
 Azathioprine (Imuran) 3 (12.0%) 3 (30.0%) 0 (0%)
 Mycophenolate Mofetil (CellCept), or Mycophenolic acid or MMF 17 (68.0%) 9 (90.0%) 8 (53.3%)
 Tacrolimus, Sirolimus or Cyclosporin 4 (16.0%) 2 (20.0%) 2 (13.3%)
 Cyclophosphamide (Cytoxan) 10 (40.0%) 5 (50.0%) 5 (33.3%)
 Belimumab (Benlysta) 8 (32.0%) 4 (40.0%) 4 (26.7%)
 Methotrexate 9 (36.0%) 2 (20.0%) 7 (46.7%)
 Prednisone or other steroids 23 (92.0%) 10 (100%) 13 (86.7%)
 Other3 8 (32.0%) 1 (10.0%) 7 (46.7%)
Lupus has previously or currently affected kidneys
 Yes 15 (60.0%) 7 (70.0%) 8 (53.3%)
 No 7 (28.0%) 2 (20.0%) 5 (33.3%)
 Don’t know 3 (12.0%) 1 (10.0%) 2 (13.3%)
Currently on dialysis
 Yes 3 (12.0%) 2 (20%) 1 (16.7%)
 No 22 (88.0%) 8 (80.0%) 14 (93.3%)
Experienced being hospitalized for more than 24 h because of a lupus flare
 Yes 19 (76.0%) 9 (90.0%) 10 (66.7%)
 No 6 (24.0%) 1 (10.0%) 5 (33.3%)